SCHEMBL167787

SCHEMBL167787

[2H]C([2H])([2H])Oc1ccc(Cl)cc1N

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.52
MAPT P10636 5/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
KDM4E B2RXH2 3/20 0.52
KMT2A Q03164 3/20 0.52
CYP1A2 P05177 2/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2C19 P33261 2/20 0.52
MEN1 O00255 2/20 0.52
HPGD P15428 2/20 0.52
CYP2D6 P10635 1/20 0.52
CYP3A4 P08684 5/20 0.50
L3MBTL1 Q9Y468 1/20 0.47
TSHR P16473 4/20 0.46
ALOX15 P16050 3/20 0.46
TDP1 Q9NUW8 1/20 0.46
TP53 P04637 1/20 0.45
GAA P10253 4/20 0.45
LMNA P02545 2/20 0.45
HTT P42858 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL92069 0.85 ALDH1A1 (0.59) ALDH1A1MAPTSMN1; SMN2KDM4EKMT2A
SCHEMBL29565516 0.85 ALDH1A1 (0.59) ALDH1A1MAPTSMN1; SMN2KDM4EKMT2A
Hydrochloric Acid SCHEMBL365099 0.83 ALDH1A1 (0.61) ALDH1A1MAPTSMN1; SMN2KDM4EKMT2A
SCHEMBL5863619 0.76 MAPT (0.73) ALDH1A1MAPTSMN1; SMN2KDM4EKMT2A
SCHEMBL30467622 0.76 SMN1; SMN2 (0.40) ALDH1A1MAPTSMN1; SMN2KDM4EKMT2A
SCHEMBL3787529 0.73 ALDH1A1 (0.53) ALDH1A1MAPTSMN1; SMN2KDM4EKMT2A
SCHEMBL30912628 0.73 CYP3A4 (0.43) ALDH1A1CYP3A4TSHRLMNA
SCHEMBL1667932 0.73 ENPP2 (0.38) ALDH1A1MAPTKDM4EKMT2AMEN1
Nitrogen SCHEMBL28057126 0.72 MAPT (0.68) ALDH1A1MAPTSMN1; SMN2KDM4EKMT2A
SCHEMBL30259322 0.72 TRPV4 (0.38) ALDH1A1MAPTSMN1; SMN2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611806-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS Ascepion Pharmaceuticals, Inc. (CN) 2013-07-10 EP disclosed
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2013-06-27 US disclosed
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2013-06-27 US disclosed
WO-2012028106-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK2, CDK1, CDK3 ALDH1A1 4512/4885MAPT 1276/4885SMN1; SMN2 3318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.